About the DTU
› Home page
Software
› HOMA Calculator
Current Studies
› 4-T
Completed Studies
› ADOPT
Intranet
Search
| A Diabetes Outcomes Progression Trial |  |
 |
|
Home page |
|
|
ADOPT is a pragmatic, real-life, double-blind, randomised multicentre study which is evaluating specifically whether thiazolidinediones, with their different mode of action, can provide more durable glycaemic control than metformin or sulphonylureas. By utilising a monotherapy approach, in people with T2DM diagnosed for less than three years who are antihyperglycaemic agent naïve, ADOPT is designed to compare the relative efficacy of these three oral agents as judged primarily by the time to monotherapy failure. ADOPT will provide data on the effect of mechanistically differing treatment options on metabolic control, beta cell function, and markers of macrovascular disease risk in type 2 diabetes. NewsNo recent news articles exist |
|
 |
|
|
|
